Deep tech cancer diagnostics advance with Morphle Labs Series A funding

Bengaluru based Morphle Labs has secured fresh capital to scale its automation platforms for cancer diagnostics as demand grows in global markets. The Morphle Labs Series A funding round of 5 million dollars is led by Inflexor Ventures and will support manufacturing, research and regulatory efforts for the deep tech healthcare automation company.

The company plans to use the capital to scale manufacturing of its flagship platforms RoboTome and MorphoLens to meet rising international demand. Funds will also be directed toward expanding its intellectual property portfolio across global jurisdictions and advancing regulatory certifications that are essential for commercialising medical devices.

In parallel, Morphle will grow its engineering, research and product teams across robotics, vision systems, optics, hardware, medical grade software and compliance. The aim is to reinforce its technical depth while supporting deployment in clinical environments that require high reliability and strict controls.

Founded in 2017 by Rohit Hiwale, Morphle Labs builds robotic and imaging systems that automate key steps in histopathology, the core workflow behind cancer diagnostics. The company is targeting one of the most underserved parts of healthcare, where many processes still rely on manual work.

RoboTome is described as a first of its kind robotic microtome capable of slicing biopsy blocks at more than twice the speed of an experienced histotechnologist while maintaining consistent section quality. MorphoLens, its complementary platform, is a high throughput slide scanner that digitises more than 100 slides per hour using robust optics and artificial intelligence driven imaging. Together, they automate some of the most complex and historically manual parts of histology and create an end to end workflow designed to improve speed, reliability and clinical readiness.

Morphle has filed more than 80 patents across robotics, optics, embedded systems and imaging, reflecting a strong research culture.

Beyond these products, the company is building integrated automation layers across the tissue diagnostics workflow, aiming to create a seamless pipeline powered by artificial intelligence and robotics. This approach is intended to reduce diagnostic turnaround times and improve outcomes for cancer patients worldwide.

Morphle team of around 100 people is based mainly in Bengaluru and Boston, with an expanding commercial presence in the United States and Europe.

Founder and chief executive Rohit Hiwale said the company vision is to rethink healthcare from the ground up, starting with histology as a domain that has not yet experienced true automation. He noted that RoboTome and MorphoLens address two major bottlenecks in diagnostics but that the larger opportunity lies in connecting every step in the chain so that labs can deliver faster, higher quality results and pathologists can focus on diagnosis.

Pratip Mazumdar, partner at Inflexor Ventures, said Morphle is transforming an overlooked yet mission critical segment of healthcare by combining robotics, imaging and artificial intelligence in clinically reliable systems. He pointed to early traction with leading labs in the United States and Europe as evidence of both the scale of the problem and the company ability to address it.

Follow Marketing Moves on Instagram and Facebook for industry insights, strategy breakdowns, and brand transformation stories.